# Increasing the Uptake of Herpes Zoster Vaccinations via Community Pharmacies

Presented at the American Academy of Dermatology (AAD) 72nd Annual Meeting Denver, CO, March 21-25, 2014

Granting state-authorized pharmacist immunization privileges for herpes zoster vaccine significantly improved herpes zoster vaccination uptake rates.

# BACKGROUND


- Herpes zoster (shingles) is a disease characterized by a painful skin rash and blistering.<sup>1</sup>
- One million cases are estimated to occur annually in the United States, half of which are among the elderly.<sup>1</sup>
- If untreated, 50% of persons ≥ 60 years old develop postherpetic neuralgia (PHN), a debilitating syndrome that can
  persist for years.<sup>2</sup>
- The Centers for Disease Control and Prevention recommends the herpes zoster vaccine to persons aged ≥ 60 years to reduce the risk of shingles and PHN2; however, coverage levels are estimated at only 15.8%.<sup>3</sup>
- Physicians typically do not stock the vaccine due to cost, storage requirements, and limited shelf life.<sup>4,5</sup>
- Pharmacists at retail pharmacies are uniquely positioned to administer these vaccinations and to share vaccination records with patients' physicians.<sup>6</sup>
- Traditionally, pharmacists provided vaccinations only per physician's order.<sup>7</sup>
- Recently, Massachusetts (May 2012), Florida (July 2012), and New York (October 2012) passed legislation allowing
  pharmacists to administer herpes zoster vaccinations per protocol or with a patient-specific prescription.<sup>7</sup>

## OBJECTIVE

• To investigate the uptake of herpes zoster vaccinations in community pharmacies and the influence of stateauthorized pharmacist immunization privileges on vaccination uptake rates.

### METHODS


- This cross-sectional study analyzed herpes zoster vaccination records from 2012 administered at the Walgreens
  pharmacy chain.
- Vaccination uptake rates were calculated as the number of patients aged ≥ 60 years who received a herpes zoster vaccine per 1,000 pharmacy patients ≥ 60 years filling a prescription for any medication at Walgreens during the study period.
- Rates of vaccinations were examined three months before and after implementation of pharmacist immunization privilege for herpes zoster in Massachusetts (May 2012), Florida (July 2012), and New York (October 2012).



\*DC authorized to administer Zostavax with a patient specific prescription

# RESULTS

- In Massachusetts, the rate of herpes zoster vaccinations per 1,000 pharmacy patients increased from 3.3 to 28.1 after pharmacists were authorized to administer vaccinations under a protocol, a 745% increase (*P*<.001).
- In Florida, the vaccination rate increased from 3.4 to 16.2, a 377% increase (P <.001). In New York, vaccination rate increased 803% from 1.3 to 11.6 (P <.001). These states authorized pharmacists to administer vaccinations with a patient-specific prescription.</li>



#### CONCLUSIONS

- After the legislation, study pharmacies had a significantly higher rate of herpes zoster vaccinations than prior to the legislation. Uptake rate was highest in Massachusetts, which granted pharmacists full authorization to administer the vaccinations.
- Results suggest that community pharmacists provided additional access and convenience to herpes zoster vaccinations for high-risk populations, resulting in increased uptake.
- Given the suboptimal vaccination rate of herpes zoster, states with limited or no immunization authorization for pharmacists should consider expanding pharmacist privileges.

#### References:

1. Centers for Disease Control & Prevention (CDC). Shingles (Herpes Zoster) Overview. 2011;

http://www.cdc.gov/shingles/about/overview.html.

2. Harpaz R, Ortega-Sanchez IR, Seward JF. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep.* Jun 6 2008;57(RR-5):1-30; quiz CE32-34. '

3. Centers for Disease Control & Prevention (CDC). Non influenza vaccination coverage among adults - United States, 2011. MMWR Morb Mortal Wkly Rep. Feb 1 2013;62(4):66-72.

4. Chen PW. Why Patients Aren't Getting the Shingles Vaccine. The New York Times Health. June 10, 2010.

5. Freed GL, Clark SJ, Cowan AE, Coleman MS. Primary care physician perspectives on providing adult vaccines. Vaccine. Feb 17 2011;29(9):1850-1854.

6. Postema AS, Breiman RF. Adult immunization programs in nontraditional settings: quality standards and guidance for program evaluation. MMWR Recomm Rep. Mar 24 2000;49(RR-1):1-13.

7. American Pharmacists Association and Academy of Managed Care Pharmacy. Pharmacist-provided immunization compensation and recognition: White paper summarizing APhA/AMCP stakeholder meeting. J Am Pharm Asssoc. Nov/Dec 2011;51(6):704-712.

#### AMA Citation:

Fensterheim, L, Taitel, M, Cannon, A, Leider, H. Increasing the uptake of Herpes Zoster vaccinations via community pharmacies. Presented at the American Academy of Dermatology (AAD) 72nd Annual Meeting; March 21-25, 2014; Denver, CO.

Contributing Authors:

Leonard Fensterheim, MPH; Michael Taitel, PhD; Adam Cannon, MPH; Harry Leider, MD Walgreens, Deerfield, IL

For more information on this presentation, please contact: research@walgreens.com. This research was funded internally by Walgreen Co. All authors are employees of the employer, Walgreen Co., for whom this research was conducted.